This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Wilkins T, Pepitone C, Alex B, Schade RR. Diagnosis and management of IBS in adults. Am Fam Physician. 2012;86:419-426.22963061WilkinsTPepitoneCAlexBSchadeRRDiagnosis and management of IBS in adults201286419426Search in Google Scholar
Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56:1770-1798.10.1136/gut.2007.11944617488783SpillerRAzizQCreedFGuidelines on the irritable bowel syndrome: mechanisms and practical management20075617701798209572317488783Open DOISearch in Google Scholar
Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004;10:299-309.15298528HuliszDThe burden of illness of irritable bowel syndrome: current challenges and hope for the future20041029930910.18553/jmcp.2004.10.4.29915298528Search in Google Scholar
Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39:1033-1042.10.1111/apt.1272824665829DupontHLReview article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets2014391033104224665829Open DOISearch in Google Scholar
Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 2015;12:36-49.10.1038/nrgastro.2014.20025446728ÖhmanLTörnblomHSimrénMCrosstalk at the mucosal border: importance of the gut microenvironment in IBS201512364925446728Open DOISearch in Google Scholar
Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014;20:8859-8866.25083059HylandNPQuigleyEMBrintEMicrobiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions20142088598866Search in Google Scholar
Hussain Z, Quigley EM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23:465-471.1644146610.1111/j.1365-2036.2006.02776.xHussainZQuigleyEMSystematic review: complementary and alternative medicine in the irritable bowel syndrome20062346547116441466Search in Google Scholar
Jarcho JM, Chang L, Berman M, et al. Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. Aliment Pharmacol Ther. 2008;28:344-352.1908633210.1111/j.1365-2036.2008.03721.xJarchoJMChangLBermanMNeural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study200828344352265643119086332Search in Google Scholar
Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149:1399-1407. e2.2625504310.1053/j.gastro.2015.07.054BöhnLStörsrudSLiljeboTDiet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial20151491399140726255043Search in Google Scholar
Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.10.1056/NEJMoa100440921208106PimentelMLemboACheyWDRifaximin therapy for patients with irritable bowel syndrome without constipation2011364223221208106Open DOISearch in Google Scholar
Pineiro M, Stanton C. Probiotic bacteria: legislative framework - requirements to evidence basis. J Nutr. 2007;137(3 suppl 2):850S-853S.1731198610.1093/jn/137.3.850SPineiroMStantonCProbiotic bacteria: legislative framework - requirements to evidence basis20071373 suppl 2850S85317311986Search in Google Scholar
Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol. 2013;19:5973-5980.2410639710.3748/wjg.v19.i36.5973DaiCZhengCQJiangMMaXYJiangLJProbiotics and irritable bowel syndrome20131959735980378561824106397Search in Google Scholar
Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.10.1186/1471-2288-7-1017302989SheaBJGrimshawJMWellsGADevelopment of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews2007710181054317302989Open DOISearch in Google Scholar
Corbitt M, Campagnolo N, Staines D, Marshall-Gradisnik S. A systematic review of probiotic interventions for gastrointestinal symptoms and irritable bowel syndrome in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Probiotics Antimicrob Proteins. 2018;10:466-477.2946450110.1007/s12602-018-9397-8CorbittMCampagnoloNStainesDMarshall-GradisnikSA systematic review of probiotic interventions for gastrointestinal symptoms and irritable bowel syndrome in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)20181046647729464501Search in Google Scholar
Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Rev Esp Enferm Dig. 2013;105:19-36.2354800710.4321/S1130-01082013000100005Ortiz-LucasMTobíasASazPSebastiánJJEffect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis20131051936Search in Google Scholar
Didari T, Mozafari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21:3072-3084.10.3748/wjg.v21.i10.307225780308DidariTMozafariSNikfarSAbdollahiMEffectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis20152130723084435693025780308Open DOISearch in Google Scholar
Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16:62.2729625410.1186/s12876-016-0470-zZhangYLiLGuoCEffects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis20161662490725827296254Search in Google Scholar
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33:1191-1197.10.1080/03007995.2017.129223028166427YuanFNiHAscheCVKimMWalayatSRenJEfficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis2017331191119728166427Open DOISearch in Google Scholar
Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547-1561; quiz 1546, 1562.10.1038/ajg.2014.20225070051FordACQuigleyEMLacyBEEfficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis201410915471561quiz 1546, 156225070051Open DOISearch in Google Scholar
Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54:243-249.10.2169/internalmedicine.54.271025748731TiequnBGuanqunCShuoZTherapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis20155424324925748731Open DOISearch in Google Scholar
Li DQ. Meta-analysis and evaluation of clinical effects of probiotics on irritable bowel syndrome (IBS). J Pract Diagnosis Ther. 2016;27:4531-4533 (in Chinese).LiDQMeta-analysis and evaluation of clinical effects of probiotics on irritable bowel syndrome (IBS)20162745314533(in Chinese)Search in Google Scholar
Zhao ZF, Yang T, Yao P. Meta-analysis of the efficacy of probiotics in the treatment of irritable bowel syndrome. Chin J New Drugs Clin Remed. 2014;33:26-35 (in Chinese).ZhaoZFYangTYaoPMeta-analysis of the efficacy of probiotics in the treatment of irritable bowel syndrome2014332635(in Chinese)Search in Google Scholar
Shu XC, Zhou SP, Chen CY, Wang SD, Wang FY. A systematic evaluation of the randomized controlled trial of irritable bowel syndrome with probiotics. Chin J Evidence-Based Med. 2012;12:840-847 (in Chinese).ShuXCZhouSPChenCYWangSDWangFYA systematic evaluation of the randomized controlled trial of irritable bowel syndrome with probiotics201212840847(in Chinese)Search in Google Scholar
Yao L, Fu L, Zhao SJ. Meta-analysis of the clinical efficacy of probiotics in the treatment of irritable bowel syndrome in China. Chin J Evidence-Based Med. 2012;12:602-607.YaoLFuLZhaoSJMeta-analysis of the clinical efficacy of probiotics in the treatment of irritable bowel syndrome in China201212602607Search in Google Scholar
Hu Y, Tao L, Lyu B. A meta-analysis of probiotics for the treatment of irritable bowel syndrome. Chin J Internal Med. 2015;54:445-451.HuYTaoLLyuBA meta-analysis of probiotics for the treatment of irritable bowel syndrome201554445451Search in Google Scholar
Lan Y, Luo HS. A meta-analysis of probiotics in the treatment of irritable bowel syndrome. J Gastroenterol Hepatol. 2011;20:809-813.LanYLuoHSA meta-analysis of probiotics in the treatment of irritable bowel syndrome201120809813Search in Google Scholar
Salem AE, Singh R, Ayoub YK, Khairy AM, Mullin GE. The gut microbiome and irritable bowel syndrome: state of art review. Arab J Gastroenterol. 2018;19:136-141.10.1016/j.ajg.2018.02.00829935865SalemAESinghRAyoubYKKhairyAMMullinGEThe gut microbiome and irritable bowel syndrome: state of art review20181913614129935865Open DOISearch in Google Scholar
Ferguson LR, Laing B, Marlow G, Bishop K. The role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: focus on genetic and genomic technologies. Mol Nutr Food Res. 2016;60:119-133.2625117710.1002/mnfr.201500243FergusonLRLaingBMarlowGBishopKThe role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: focus on genetic and genomic technologies20166011913326251177Search in Google Scholar
Martínez C, González-Castro A, Vicario M, Santos J. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver. 2012;6:305-315.2284455710.5009/gnl.2012.6.3.305MartínezCGonzález-CastroAVicarioMSantosJCellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome20126305315340416622844557Search in Google Scholar
Major G, Spiller R. Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes. 2014;21:15-21.2429646210.1097/MED.0000000000000032MajorGSpillerRIrritable bowel syndrome, inflammatory bowel disease and the microbiome2014211521387140524296462Search in Google Scholar
Jiang T, Savaiano DA. Modification of colonic fermentation by bifidobacteria and pH in vitro. Impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci. 1997;42:2370-2377.JiangTSavaianoDAModification of colonic fermentation by bifidobacteria and pH in vitro1997422370237710.1023/A:1018895524114Search in Google Scholar